Minoxidil alone may not stop hair loss. Finasteride is recommended for androgenic alopecia, as minoxidil doesn't prevent DHT from miniaturizing hairfollicles.
A user likes a natural hair styling product that makes their hair look thicker and is seeking opinions on whether it could harm hairfollicles. They also question if cold water is sufficient to wash the product out and mention they are experiencing hair thinning.
ET-02, a new hair loss treatment, shows promising results with a 6-fold increase in hair count, potentially outperforming minoxidil by activating stem cells in hairfollicles. Further trials are ongoing to confirm its efficacy and safety, with potential market release in the future.
The conversation is about using Verteporfin with microneedling as a potential hair loss treatment that may regenerate hairfollicles with minimal scarring. There are concerns about the optimal dosage and the DHT sensitivity of the new follicles.
The user is seeking advice for the best topical treatment to combat their ongoing hair loss, despite already using oral dutasteride, RU-58841, and minoxidil. They are considering adding CB-03-01 or topical Spiro to their regimen to lower testosterone levels at the follicles.
A 31-year-old man with a long history of hair care is considering a hair transplant and is worried about using Finasteride and Minoxidil due to potential side effects. He seeks advice on whether to start Finasteride before or after a transplant and how to test for sensitivity to these treatments.
Breezula protects hairfollicles from both testosterone and DHT, unlike finasteride, which only protects against DHT. This could potentially lead to significant hair regrowth, similar to results seen in transgender individuals using hormone blockers.
HairClone aims to rejuvenate miniaturizing hairfollicles through follicle banking and cell expansion, with treatments potentially available in the UK by 2022. The process involves extracting, storing, and cloning hairfollicles, but full regenerative treatments will take many years to develop.
Hair loss treatment should target dermal white adipose tissue (DWAT) to restore hairfollicles. Potential remedies include tocopherol (vitamin E), botox, rosiglitazone, niacin, kojyl cinnamate esters, and ADP355.
Hair loss may be caused by calcification of capillaries in the scalp, restricting blood flow to hairfollicles. A daily treatment regimen including high doses of Vitamins D and K, Magnesium, and Nattokinase could potentially decalcify these capillaries, improving blood flow and hair growth. However, some users warn against excessive Vitamin D intake and emphasize the need for medical consultation.
Hair loss treatments like Minoxidil and Finasteride will still be used even if a cure is found. Hair transplants will continue as cloning new hairfollicles will be part of the process.
PP405 is not a cure for hair loss but may reactivate dormant hairfollicles, similar to minoxidil. It is unlikely to help with miniaturized or vellus hairs and is still in trial phases, with availability expected around 2030.
The conversation discusses hair loss where only short, thin hairs are being shed after 16 weeks of using dutasteride, with no visible regrowth. One response suggests that shedding short hairs is a positive sign, indicating that the hairfollicles are still active and responding to treatment.
Fluridil may decrease the number of androgen receptors in hairfollicles by up to 95%. This suggests a different action mechanism from other non-steroidal antiandrogens like RU58841, indicating they might be used together.
Finasteride prevents further hair loss by blocking DHT, while minoxidil stimulates hair growth by prolonging the active phase of hairfollicles. Stopping minoxidil can lead to loss of regrown hair because finasteride does not address the same growth mechanism.
Finasteride stops hair loss by blocking DHT, while Minoxidil promotes hair growth by increasing blood flow to hairfollicles. Using both can help regrow hair, but results vary by individual.
The conversation discusses GT20029 as a potential hair loss treatment that could act like a cure by targeting androgen receptors in scalp hairfollicles. Specific treatments mentioned include GT20029, with a user expressing hope that it could make male pattern baldness obsolete.
Male pattern baldness (MPB) may be influenced by androgen receptors in scalp hairfollicles and potentially poor blood flow. Transplanted hair is not immune to DHT, and factors like inflammation and scalp tension might also contribute to hair loss.
Verteporfin is being explored for its potential to improve hair transplant outcomes by reducing scarring and increasing donor hairfollicles. There is skepticism about the results, with some claiming misleading presentation of evidence.
The conversation discusses hair loss treatments, focusing on the use of topical minoxidil, microneedling, finasteride, and dutasteride, while debating the role of testosterone and DHT in hair loss. It also touches on the potential liver health impacts of these treatments and the genetic sensitivity of hairfollicles to androgens.
The user discusses their hair loss experience, exploring various hypotheses including thyroid levels, vitamin D, DHEA, nutritional deficiency, diabetes, seborrheic dermatitis, lack of nutrition to hairfollicles, chronic inflammation, female pattern hair loss causes, cortisol, and prolactin levels. They are currently using finasteride, beta-sitosterol, and have tried topical dutasteride and microneedling therapy.
The conversation discusses starting Minoxidil for hair loss and suggests also using finasteride to prevent further balding. Minoxidil is expected to thicken current hair, but won't stop hairfollicles from dying.
User "Ant1pal" shares progress pictures of hair regrowth using Minoxidil, Estradiol valerate, and Spironolactone. Users discuss potential side effects and the possibility of localizing estrogen to hairfollicles for better treatment.
The conversation discusses concerns about the potential risk of cancer from creating new hairfollicles through microneedling, due to stem cell division. Specific treatments mentioned include microneedling, caffeine-containing anti-hair loss shampoos, and other unspecified topicals.
Some individuals do not respond to oral minoxidil for hair loss, despite it generally working by improving blood flow to hairfollicles. Factors like metabolism, drug interactions, and individual variations in the drug's activation may influence its effectiveness.
GHK-Cu is a potent inhibitor of the type 1 5-alpha reductase enzyme in hairfollicles, which may reduce hair loss without the side effects associated with type 2 5-alpha reductase inhibitors. The user previously experienced side effects with 5-alpha reductase inhibitors and is considering GHK-Cu as an alternative.
The conversation discusses the use of Verteporfin in hair loss treatment. It suggests that Verteporfin could potentially regenerate hairfollicles instead of forming scars, providing an unlimited donor supply for hair transplants.
The post discusses the theory that persistent dandruff in areas prone to hair loss could be a sign of hairfollicles dying due to DHT, indicating balding. The responses vary, with some users noting improvements in dandruff and hair loss with treatments like Dutasteride, while others experienced hair loss without dandruff.